Related Experiment Video
Updated: Mar 13, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Rationale and design of Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic
Anxin Wang1,2,3, Jing Li1,2,3, Xiaoli Zhang1,2,3
1Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Background:
Shuxuening injection (SXNI), a multi-target cerebroprotectant, holds promise as adjuvant therapy to intravenous thrombolysis (IVT) in acute ischemic stroke (AIS), but its efficacy has not yet been established.
Aim:
The aim of this study was to present the rationale and design of the Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) trial.
Design:
This multicenter, randomized, double-blind, placebo-controlled trial sought to evaluate the efficacy and safety of SXNI in AIS patients undergoing IVT. The estimated sample size is 1380 patients. Eligible participants aged ≥ 18 years with symptom onset within 6 h, who are receiving or planned for IVT and have a baseline National Institutes of Health Stroke Scale score of 4-25, will be randomly assigned (1:1) to receive either SXNI or placebo for 10-14 days.
Study Outcomes:
The primary efficacy outcome is the proportion of patients with favorable functional outcome (modified Rankin Scale score of 0-1) at 90 days. The primary safety outcome is the adverse events within 90 days.
Discussion:
The SHINY trial will provide evidence on whether SXNI exerts cerebroprotective effect in IVT-treated AIS patients.
Trial Registration:
ClinicalTrials.gov (identifier: NCT06157502).
